Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798142 | 0.83 | MAPT (0.64) | KMT2AMEN1MAPTSMN1; SMN2PLAU | |
| SCHEMBL4796598 | 0.81 | KMT2A (0.49) | KMT2AMEN1MAPTSMN1; SMN2PLAU | |
| SCHEMBL4795125 | 0.81 | GRM4 (0.50) | KMT2AMEN1MAPTSMN1; SMN2PLAU | |
| SCHEMBL4796549 | 0.79 | KDM4E (0.47) | KMT2AMEN1SMN1; SMN2KEAP1GRM4 | |
| SCHEMBL29888246 | 0.79 | KEAP1 (0.44) | KMT2AMEN1MAPTKEAP1KDM4E | |
| SCHEMBL4800383 | 0.79 | KEAP1 (0.44) | KMT2AMEN1MAPTKEAP1KDM4E | |
| SCHEMBL28502195 | 0.79 | MAPT (0.43) | KMT2AMEN1MAPTSMN1; SMN2PLAU | |
| SCHEMBL12593846 | 0.79 | KEAP1 (0.62) | KMT2AMEN1MAPTSMN1; SMN2KEAP1 | |
| SCHEMBL28511356 | 0.79 | HTT (0.36) | KMT2AMEN1KEAP1KDM4EALDH1A1 | |
| SCHEMBL4798011 | 0.78 | ALDH1A1 (0.37) | KMT2AMEN1MAPTSMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | claimed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | claimed |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
| CN-108947918-B | Diamine monomer containing pyrazine structure and preparation method thereof, polyimide containing pyrazine structure and preparation method thereof | 吉林大学 | 2021-01-15 | — | — | CN | disclosed |
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-11-19 | — | — | US | disclosed |
| US-10556860-B2 | hTERT modulators and methods of use | ARIZONA BOARD OF REGENTS (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180346415-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2018-12-06 | — | — | US | disclosed |
| EP-3383841-A1 | hTERT MODULATORS AND METHODS OF USE | The Arizona Board of Regents On Behalf of the University of Arizona (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017095969-A1 | hTERT MODULATORS AND METHODS OF USE | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-06-08 | — | — | WO | disclosed |
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | disclosed |
| US-6890924-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | KMT2A 211/4885MEN1 1334/4885MAPT 2982/4885 |
| US-10556860-B2 | hTERT modulators and methods of use | TERT, POT1, TERF2 | KMT2A 606/4885MEN1 1731/4885MAPT 2846/4885 |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | KMT2A 3339/4885MEN1 1199/4885MAPT 4429/4885 |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | KMT2A 3112/4885MEN1 331/4885MAPT 4353/4885 |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | KMT2A 195/4885MEN1 1581/4885MAPT 3677/4885 |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | KMT2A 2263/4885MEN1 1605/4885MAPT 3779/4885 |
| US-20180346415-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, POT1, TERF2 | KMT2A 606/4885MEN1 1731/4885MAPT 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.